东方民丰回报赢安混合A/C成立于2017年3月9日，截至2025年11月24日，其今年来收益率为 2.17%、1.94%，成立来收益率为6.82%、4.22%，累计净值为1.0681元、1.0424元。 | 基金名称 | 东方民丰回报赢安混合型证券投资基金 | | --- | --- | | 基金简称 | 东方民丰回报赢安混合 | | 基金主代码 | 004005 | | 基金管理人名称 | 东方基金管理股份有限公司 | | 公告依据 | 《公开募集证券投资基金信息披露管理办法》、《基金管理公司投资 | | | 管理人员管理指导意见》等 | | 基金经理变更类型 | 增聘基金经理、解聘基金经理 | | 新任基金经理姓名 | 徐奥千 | | 共同管理本基金的其他经 | | | 理姓名 | | | 离任基金经理姓名 | 张博 | 中国经济网北京11月25日讯 今日，东方基金公告，东方民丰回报赢安混合增聘徐奥千，张博离 任。 徐奥千曾任神雾集团证券专员。2017年加盟东方基金，曾任固定收益研究部研究员、交易部债券交 易员，基金经理助理、基金经理。 （责任编辑：康博） ...

Core Insights - The performance of multiple products managed by Wang Ran, the general manager of the equity research department at Dongfang Fund, has been persistently poor, leading to significant dissatisfaction among investors [1][3] - Dongfang Fund, a long-established public fund institution, has faced challenges with a high number of "mini funds" and several equity products at risk of liquidation [1][4] Group 1: Fund Performance - Wang Ran currently manages three products with a total asset management scale of 205 million yuan, and the best return during her tenure is -10.19%, marking the worst performance of her public fund career [3] - The Dongfang Emerging Growth Mixed Fund has seen a slight increase of 0.06% this year, ranking 2133 out of nearly 2300 similar products, while the Dongfang Quality Consumption One-Year Holding Mixed A ranks 4154 out of over 4500 similar products [3] - Over the past three years, the Dongfang Emerging Growth Mixed Fund has a return rate of approximately -40%, underperforming its benchmark by about 43 percentage points [3] Group 2: Company Challenges - Dongfang Fund, established in 2004, had a public fund asset management scale of 123.405 billion yuan as of mid-year, ranking 53rd among nearly 200 public fund institutions [4] - The company faces liquidation pressure, with 11 non-initiated funds having scales below 50 million yuan, including the Dongfang Minfeng Return Ying'an Mixed Fund with less than 3 million yuan [4] - Wang Ran previously had successful tenures from 2020 to 2021, with returns ranging from 4% to 68%, but her focus on pharmaceutical stocks since mid-2021 has led to significant declines in performance and a reduction in management scale [4]